In April 2016,pimavanserin was approved by the FDA as the first drug for hallucinations and delusions in pa-tients with Parkinson's disease.Pimavanserin is a reversible agonist of selective serotonin 2A receptor with a plasma t1/2 of about 57 hours,Tmax of 6 hours,and is metabolized by the cytochrome P4503 A4 enzyme,and the concomitant use of pima-vanserin with an inhibitor or inducer of this enzyme should be used with vigilance for the occurrence of drug interactions.In re-cent years,there has been a gradual increase in the number of indication areas for conducting clinical trials of pimavanserin,mainly for phase Ⅱ,Ⅲ,and Ⅳ.Pimavanserin has been found to have clear efficacy and safety not only for psychiatric symp-toms in patients with Parkinson's disease,but also may have therapeutic potential for major depression,dementia-related psy-chosis,Alzheimer's disease-related psychosis,schizophrenia-negative symptoms,obstructive sleep apnea,and post-traumat-ic stress disorder.
NETL
NSTL
万方数据
